Previous 10 |
Synaptogenix to Present at the H.C. Wainwright Global Life Sciences Conference PR Newswire NEW YORK , March 5, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerati...
Synaptogenix to Present at Upcoming Scientific Industry Conferences PR Newswire NEW YORK , Feb. 25, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases...
Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference PR Newswire NEW YORK , Feb. 12, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), an emerging biopharmaceutical company focused on developing therapies for...
Synaptogenix Files Application to List on the Nasdaq Stock Market PR Newswire NEW YORK , Feb. 9, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) (the "Company"), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative...
Synthetic Bryostatin Available to Expand Neurodegenerative Indication Trials PR Newswire NEW YORK , Feb. 4, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX) announced today that it has received its first batch of synthetic Bryostatin. The Company has an e...
New Study Demonstrates Bryostatin Normalizes Autistic Spectrum Behaviors in Mice - Peer Reviewed Article Published through Nature.com PR Newswire NEW YORK , Jan. 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience...
Synaptogenix (SNPX) formerly Neurotrope Bioscience, to raise ~$14M in a private placement of common stock at $1.50/share, one-year warrants to purchase an equal number of common stock at $2.1275 and five-year warrants to purchase an equal number of common stock at $1.725 per share. Proceeds w...
Synaptogenix Announces $14.0 Million Private Placement - Fully Funds Phase 2 Alzheimer's Disease Trial Being Conducted in Partnership with The National Institutes of Health - Provides Pathway for Strategic Partnerships on Other Indications PR Newswire NEW YORK ...
Synaptogenix Schedules Business Update Conference Call NEW YORK , Dec. 15, 2020 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., announced the successful spin-off of substantially all of the legacy assets and liabilities of ...
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury PR Newswire Company holds exclusive rights to family of polyunsaturated fatty acid (PUFA) analogs New patent covers proprietary analogs in ...
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...